Family matters

Mrsa: - The rate doubles, and it's probably worse

For years now we've been saying that hospitals are a dangerous place to be, especially if you're ill. The latest figures from the British government - which show a doubling of deaths from the MRSA superbug over the past four years - confirm this view.
The Office for National Statistics reveals that MRSA was cited as the cause of death in 955 cases in 2003, up from 487 in 1999.
Worrying as the figures are, experts reckon they are still seriously under-stated. Tony Field, chairman of the patient group MRSA Support, said that patients are dying in hospital from the superbug, but their illness is cited as the cause. "A cancer patient may get MRSA and die, but cancer will be cited as the cause of death, but MRSA would have played a contributing role. I would expect the true figure to be much more than 955," he told the BBC.

Related WDDTY Content

New drugs - New profits for old product

Most new drugs are simply old drugs with a bit of window dressing to justify double the price tag. Yet, the dangers multiply from these novel twists a...

Lyme disease rate doubles in a decade

The incidence of new cases of Lyme disease has doubled in the US since 1991, according to the US Centers for Disease Control (CDC)

Astroturfing: Why the information on patient group sites can be suspect

There are plenty of tactics that drug companies employ in order to increase sales. Getting to doctors is easy enough: ‘educational’ trips to the Car...

New drugs: - Keeping those profits rolling in

The drugs industry thrives on novelty. Claims for the great new wonder drug fuel shareholder interest, which in turn pushes up the share price. Bett...

New drugs at least they cost a lot more

New drugs are the lifeblood of the pharmaceutical industry, as they account for around a third of a drug company’s profits every year. There’s usually...

New drugs for old: - How drug companies make their profits

No E-news bulletin would be complete without some news about those bad, bad boys, the drug companies. This week we hear that GlaxoSmithKline has been...